𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Talipexole and adult Gilles de la tourette's syndrome: Double-blind, placebo-controlled clinical trial

✍ Scribed by Dr. Christopher G. Goetz; Glenn T. Stebbins; Jean A. Thelen

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
288 KB
Volume
9
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Talipexole is a new dopamine autoagonist with putative preferential activity on presynaptic dopamine receptors. In a double‐blind, placebocontrolled study, we tested the drug's safety and efficacy in 13 adult men with Gilles de la Tourette's syndrome. The drug was poorly tolerated because of clinically significant sedation and dizziness. Tics did not improve at tolerable doses. These findings suggest that talipexole has no role in the regular management of tic disorders.

📜 SIMILAR VOLUMES

Etanercept in Sjögren's syndrome: A twel
Etanercept in Sjögren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial
✍ Vidya Sankar; Michael T. Brennan; Marc R. Kok; Rose Anne Leakan; Janine A. Smith 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Abstract ## Objective To assess the safety and potential efficacy of etanercept in the treatment of Sjögren's syndrome (SS). ## Methods This pilot study was a 12‐week randomized, double‐blind, placebo‐controlled trial of etanercept, with 14 subjects in each group. Patients received 25 mg of e